Publications by authors named "Yoichi Hazama"
Introduction: Non-esophageal eosinophilic gastrointestinal disorders (non-EoE EGIDs) are rare, but their prevalence has recently increased. Although it has been reported that one-half of patients with non-EoE EGIDs have intractable clinical courses, their clinical features are not fully understood.
Methods: This is a multicenter retrospective study in which 10 institutions in Japan participated.
Article Synopsis
- This study explored how being overweight affects the outcomes of ablation therapy in early-stage hepatocellular carcinoma (HCC) patients, analyzing data from 198 individuals who underwent the procedure at a specific hospital.
- The participants were categorized based on their body mass index (BMI) into overweight (BMI ≥ 25 kg/m²) and non-overweight (BMI < 25 kg/m²), revealing that technical success rates were significantly lower in overweight patients during the first session.
- Interestingly, despite the initial technical challenges, overweight patients showed better overall survival rates compared to non-overweight patients, suggesting that the impact of being overweight could be less significant in terms of long-term outcomes for HCC patients receiving ablation therapy.
Article Synopsis
- An 81-year-old man had surgery to remove part of his liver due to cancer and was diagnosed with combined hepatocellular and cholangiocarcinoma (CHC).
- Thirteen months later, he developed multiple lymph node metastases, indicating the cancer had spread.
- He was treated with a combination of atezolizumab and bevacizumab (Atez/Bev), resulting in a 7.5-month period without disease progression, suggesting this treatment may work well for CHC patients.
A 66-year-old man, who had undergone plasma exchange 30 years previously in Egypt for the treatment of falciparum malaria, was referred to our hospital for treatment of chronic hepatitis C (HCV). An analysis of the 655-nucleotide 5'-untranslated region-core region sequence revealed infection with HCV subtype 1g. A phylogenetic analysis of the full-length HCV genome confirmed that the patient's HCV was subtype 1g, which was the first case identified in Japan.
View Article and Find Full Text PDFObjective The therapeutic effect of pemafibrate on metabolic dysfunction-associated fatty liver disease (MAFLD) remains unknown. This retrospective, single-arm study investigated the efficacy and safety of pemafibrate in MAFLD patients with hypertriglyceridemia. Methods A total of 10 patients who received pemafibrate (oral, 0.
View Article and Find Full Text PDF